Novartis
NVS
1,253 hedge funds and large institutions have $13.6B invested in Novartis in 2024 Q1 according to their latest regulatory filings, with 89 funds opening new positions, 425 increasing their positions, 472 reducing their positions, and 92 closing their positions.
0.1% less ownership
Funds ownership: 6.5% → 6.41% (-0.1%)
3% less first-time investments, than exits
New positions opened: 89 | Existing positions closed: 92
3% less call options, than puts
Call options by funds: $143M | Put options by funds: $148M
10% less repeat investments, than reductions
Existing positions increased: 425 | Existing positions reduced: 472
1% less funds holding
Funds holding: 1,272 → 1,253 (-19)
9% less capital invested
Capital invested by funds: $15B → $13.6B (-$1.37B)
43% less funds holding in top 10
Funds holding in top 10: 14 → 8 (-6)
Top Buyers
| 1 |
CCM
Cullen Capital Management
New York
|
+$133M |
| 2 |
Citigroup
New York
|
+$69.3M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$68.3M |
| 4 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
+$60.6M |
| 5 |
GAM
Groupama Asset Management
Paris,
France
|
+$40.6M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$710M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$83.2M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$75.4M |
| 4 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
-$59.6M |
| 5 |
Primecap Management
Pasadena,
California
|
-$50M |
NVS Hedge Fund Activity: Q1 2024 in Review
1,253 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q1 2024, worth a combined $13.6B — down 9.2% from $15B a quarter earlier.
Sellers outnumbered buyers: 92 funds closed out of NVS and 89 opened new positions — a net loss of 3 holders — while 472 trimmed existing stakes and 425 added.
The largest buyer was Cullen Capital Management, adding an estimated $133M. The largest seller was Morgan Stanley, cutting an estimated $710M.
- 1,253 institutional investors held Novartis (NVS) as of Q1 2024, down from 1,272 in Q4 2023.
- Funds reported $13.6B of Novartis stock for Q1 2024, down 9.2% quarter-over-quarter.
- 89 funds opened new Novartis positions in Q1 2024 and 92 closed out, a net change of -3 holders.
- The largest Novartis buyer in Q1 2024 was Cullen Capital Management, an estimated $133M added.
- The largest Novartis seller in Q1 2024 was Morgan Stanley, an estimated $710M sold.
Based on aggregated 13F filings for Q1 2024.